Über das Unternehmen
Imagine developing a life-saving biologic, only to realize that millions of patients may never access it because manufacturing is too complex and the drug too expensive. This is the challenge of monoclonal antibodies, a $300B market. These therapies rely on living cells, and the manufacturing process is still highly manual, requires multiple devices, and carries significant contamination risk. SW1NGO, is a single-use bioreactor incubator that enables cell culture in 1 go: 1 device, 1 consumable, fully automated. With SW1NGO, we have demonstrated up to 50% cost reduction at global biopharma companies while maintaining the same product quality. Because the real breakthrough in biologics is making them accessible to everyone who needs them.
So findest du sie
Offene Jobs3
